Radiotherapy for sinus carcinomas after surgery
Official title: Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery
Run by Centre Francois Baclesse · NCT05943119 · Data updated 2026-11-12
This study tests whether a new type of targeted radiotherapy can help people with sinus cancer feel better after surgery compared to standard treatment.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 52 (estimated) |
| Sponsor | Centre Francois Baclesse Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Caen and 2 other locations) |
| Status | Recruiting |
| Started | March 11, 2024 |
| Main results expected | January 2028 |
| Study ends | March 2029 |
| Registry record updated | July 2, 2026 |
| Trial ID | NCT05943119 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 with histologically confirmed nasosinus carcinoma who have recently undergone endoscopic sinonasal surgery.
✕Probably not a fit
Patients with distant metastases or those who have not undergone surgery for their tumor will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of intensity-modulated radiotherapy (IMRT) using a dose-painting technique based on histoscannographic mapping for patients with nasosinus carcinoma who have undergone endoscopic surgery. Participants are randomized into two groups: one receiving the experimental IMRT treatment and the other receiving standard pan-sinus radiotherapy. The goal is to determine if the tailored approach can improve outcomes while minimizing mucosal toxicity compared to conventional methods.
Why it matters
Potential benefit: If successful, this approach could lead to better treatment outcomes and reduced side effects for patients with sinus carcinomas.
How similar studies have gone: Other studies using intensity-modulated radiotherapy have shown promising results, suggesting potential success for this novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \>18 years of age * Patient with a histologically confirmed malignant tumor of the sinuses, any histological type except melanoma, lymphoma, mesenchymal tumors (sarcoma) * Patient treated by endoscopic sinonasal surgery with histosurgical mapping within 2 months prior to radiotherapy * Indication for radiotherapy treatment (photontherapy or protontherapy), without neoadjuvant chemotherapy (concomitant chemotherapy is permitted) * Signature of informed consent prior to any specific study procedure * Subject affiliated to a social security system Exclusion Criteria: * Patient with not operated in place tumor * Patient with distant metastases * Patient treated with neoadjuvant chemotherapy * Pregnant or breast-feeding woman or absence of contraception during genital activity * History of any other malignant disease in the last 3 years, except basal cell skin cancer, carcinoma in situ or superficial bladder tumor. Any other solid tumor or lymphoma (without bone marrow involvement) must have been treated and show no sign of recurrence for at least 3 years. * Simultaneous participation in another therapeutic clinical trial * Patients deprived of their liberty, under guardianship, under curatorship, or subject to a legal protection measure, or unable to express their consent. * Patients unable to undergo trial monitoring for geographical, social or psychopathological reasons
Where it's running
-
Centre Francois Baclesse
Caen, France Recruiting -
Chu Caen
Caen, France Not yet recruiting -
Centre Oscar Lambret
Lille, France Not yet recruiting
Study contacts
- Study coordinator: Vincent PATRON, MD
- Email: patron-v@chu-caen.fr
- Phone: +33231063106
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Carbon nanoparticle‑loaded iron for advanced solid tumors
This test uses direct injections of a carbon nanoparticle‑loaded iron medicine (CNSI‑Fe) to see if it can shrink tumors in adults with advanced solid cancers who have no effective standard treatment options.
-
RGL-270 vaccine alone or with adebelimab to lower risk of cancer coming back after surgery
This phase I trial will test whether a personalized mRNA vaccine called RGL-270, given alone or with the immune drug adebelimab, can help prevent recurrence in adults who had radical treatment for high‑risk malignant solid tumors.
-
Evaluating XNW29016 Tablets for Advanced Solid Tumors After Standard Treatment Failure
This study is testing if XNW29016 tablets can help people with advanced solid tumors who haven't responded to regular treatments.
-
Evaluating AD1208 for advanced solid tumors
This study is testing a new drug called AD1208 to see if it is safe and tolerable for people with advanced solid tumors.
-
Nutritional management for children with solid tumors
This study is testing a new nutrition plan to see if it helps children with solid tumors get better nutrition and improve their health.
-
Treatment for advanced solid tumors using engineered T cells
This study is testing a new treatment using specially designed T cells to see if it can help people with advanced solid tumors that haven't responded to other therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.